Pharmacology News

A 30-minute educational intervention for primary care physicians increased prescribing rates of SGLT2 inhibitors and GLP-1 agonists among patients with type 2 diabetes and risk factors for atherosclerotic CVD, according to researchers.

After 1 year of treatment, SGLT2 inhibitors were associated with a 32% lower risk for hospitalization due to heart failure, regardless of type 2 diabetes status, according to a new study in Annals of Internal Medicine.

Adolescents who reported multiple symptoms of severe substance use disorder were more likely to report these symptoms in adulthood, according to findings published in JAMA Network Open.

In patients requiring secondary CVD prevention, P2Y12 inhibitor monotherapy conferred reduced risk for major adverse CV events compared with aspirin monotherapy without raising risk for bleeding, researchers reported.

About one in four people who may have needed treatment for opioid use disorder received it in 2019, according to findings published in JAMA Network Open.

Among patients hospitalized with moderate COVID-19, those who received aspirin on the first day of hospitalization had a significantly lower risk for 28-day mortality than those who did not, according to a recent observational cohort study.

Primary care clinicians accounted for a small proportion of abortion providers in the United States in 2019, according to findings published in JAMA Internal Medicine.

Obtaining a medical marijuana card for chronic pain, insomnia, anxiety or depression led to a “rapid onset” of cannabis use disorder, according to researchers.

Compared with no antiplatelet therapy, aspirin and P2Y12 inhibitors did not improve the number of organ support-free days in critically ill patients with COVID-19, according to results of the REMAP-CAP trial published in JAMA.

The expansion of telehealth services during the COVID-19 pandemic allowed patients to remain in treatment for opioid use disorder, according to findings published in the Journal of Rural Mental Health.